NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Do you, or did you, own shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA)?Did you purchase your shares between July 30, 2024 and January 8, ...
Clinical Trials Arena on MSN3d
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PNThe trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...
American Century Companies Inc. increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 3.5% in ...
Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...
Intellia Therapeutics has commenced subject dosing in the randomised pivotal Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback